Sökning: "Azacitidine"

Visar resultat 1 - 5 av 6 avhandlingar innehållade ordet Azacitidine.

  1. 1. Improving prognostication and treatment choices for patients with AML

    Författare :Albin Österroos; Sören Lehmann; Marc H G P Raaijmakers; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Acute myeloid leukaemia; Acute promyelocytic leukaemia; Prognostication; Personalised medicine; Risk stratification; Real-world data; Next-generation sequencing; Azacitidine; Venetoclax; Medicinsk vetenskap; Medical Science;

    Sammanfattning : The treatment landscape of the aggressive haematological malignancy acute myeloid leukaemia (AML) has expanded but the prognosis is still unsatisfactory poor. Here, we aimed at improving prognostication and treatment choices in AML by addressing current clinical obstacles to successful AML treatment. LÄS MER

  3. 2. Infectious and bleeding complications in patients with hematological malignancies : Studies on diagnosis and prevention

    Författare :Tobias Svensson; Honar Cherif; Martin Höglund; Jan Sjölin; Christine Wennerås; Uppsala universitet; []
    Nyckelord :Chronic lymphocytic leukemia; Immunodeficiency; Hypogammaglobulinemia; IgG subclass; Pneumococci; Pneumococcal vaccine; Polysaccharide vaccine; Protein-conjugate vaccine; Aspergillosis; Bronchoalveolar lavage; Invasive fungal disease; Pneumocystis jirovecii pneumonia; Myelodysplastic syndrome; Azacitidine; Eltrombopag; Thrombocytopenia; Thrombopoietin receptor; Oncology; Onkologi;

    Sammanfattning : The overall aim of this thesis is to improve knowledge about the prevention of infectious and bleeding complications in patients with hematological malignancies, primarily in those with chronic lymphocytic leukemia (CLL) and myelodysplatic syndrome (MDS).Hypogammaglobulinemia, impaired production of immunoglobulins (Ig), is an established risk factor for infection, but the impact of IgG pure subclass deficiency (IgG subclass deficiency with adequate production of IgG, IgA, and IgM) has been debated. LÄS MER

  4. 3. Clinical and molecular effects of azacitidine in the myelodysplastic syndromes

    Författare :Magnus Tobiasson; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : The myelodysplastic syndromes (MDS) constitute a heterogeneous group of malignant bone marrow disorders characterized by peripheral cytopenia and increased risk of leukemic progression. In higher-risk MDS, Azacitidine has been shown to prolong survival and modulate the epigenome, although the precise mechanisms by which the drug exerts its effect are unknown. LÄS MER

  5. 4. DNA methylation and hypomethylating agents in high-risk myelodysplastic syndromes and acute myeloid leukemia

    Författare :Michael Grövdal; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Epigenetic alterations are common in cancer. One example is aberrant hypermethylation of the promoters of tumor suppressor genes and hence silencing of gene expression. LÄS MER

  7. 5. Exploring the role of epigenetic alterations in myeloid malignancies with focus on drug response

    Författare :Hani Abdulkadir Ali; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : The production of blood cells (hematopoiesis), where the hematopoietic stem cell (HSC) is the cell of origin of all blood cells, is regulated by a complex network of intrinsic and extrinsic signals. Dysregulation of hematopoiesis, including somatic heterozygous mutations, cytogenetic aberrations, or epigenetic aberrations, are found in hematological malignancies. LÄS MER